Literature DB >> 9794010

Cognitive impairment in the euthymic phase of affective disorder.

L V Kessing1.   

Abstract

BACKGROUND: A review of studies of cognition in the euthymic phase of unipolar and bipolar affective disorder reveals diverging results.
METHODS: The study was designed as a controlled cohort study, with the Danish psychiatric case register of admissions used to identify patients and the Danish civil register to identify controls. Patients who were hospitalized between 19 and 25 years ago with an affective diagnosis and who at interviews fulfilled criteria for a primary affective unipolar or bipolar disorder, according to ICD-10, were compared with age- and gender-matched controls. Interviews and assessment of the cognitive function were made in the euthymic phase of the disorder. In all, 118 unipolar patients, 28 bipolar patients and 58 controls were included. Analyses were adjusted for differences in the level of education and for subclinical depressive and anxiety symptoms.
RESULTS: Patients with recurrent episodes were significantly more impaired than patients with a single episode and more impaired than controls. Also, within patients the number of prior episodes seemed to be associated with cognitive outcome. There was no difference in the severity of the dysfunction between unipolar and bipolar patients.
CONCLUSIONS: Cognitive impairment in out-patients with unipolar and bipolar disorder appears to be associated with the number of affective episodes.

Entities:  

Mesh:

Year:  1998        PMID: 9794010     DOI: 10.1017/s0033291798006862

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  46 in total

Review 1.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

3.  Depression severity and concentration difficulties are independently associated with HRQOL in patients with unipolar depressive disorders.

Authors:  A Fattori; L Neri; A Bellomo; M Vaggi; C Mencacci
Journal:  Qual Life Res       Date:  2017-05-13       Impact factor: 4.147

4.  The role of primary care clinicians in diagnosing and treating bipolar disorder.

Authors:  Larry Culpepper
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 5.  Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Lars V Kessing
Journal:  Psychopharmacology (Berl)       Date:  2011-09-23       Impact factor: 4.530

Review 6.  [Treating depressive disorders with continuation electroconvulsive therapy].

Authors:  A Sartorius; F A Henn
Journal:  Nervenarzt       Date:  2005-11       Impact factor: 1.214

7.  Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Gitte M Knudsen; Julian Macoveanu; Allan R Hansen; Olaf B Paulson; Hartwig R Siebner; Lars V Kessing
Journal:  Trials       Date:  2010-10-13       Impact factor: 2.279

Review 8.  Lithium and cognitive enhancement: leave it or take it?

Authors:  Eleftheria Tsaltas; Dimitris Kontis; Vasileios Boulougouris; George N Papadimitriou
Journal:  Psychopharmacology (Berl)       Date:  2008-09-10       Impact factor: 4.530

9.  Cognitive functioning in major depression--a summary.

Authors:  Asa Hammar; Guro Ardal
Journal:  Front Hum Neurosci       Date:  2009-09-25       Impact factor: 3.169

10.  Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression.

Authors:  Ulla Knorr; Maj Vinberg; Marianne Klose; Ulla Feldt-Rasmussen; Linda Hilsted; Anders Gade; Eva Haastrup; Olaf Paulson; Jørn Wetterslev; Christian Gluud; Ulrik Gether; Lars Kessing
Journal:  Trials       Date:  2009-08-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.